JNJ — Johnson & Johnson Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Johnson & Johnson, fiscal year end - December 29th, USD millions except per share, conversion factor applied.

	2021 January 3rd	R2022 January 2nd	2023 December 31st	R2023 January 1st	2024 December 29th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	82,584	78,740	85,159	79,990	88,821
Cost of Revenue
Gross Profit	54,257	55,338	58,915	55,394	61,385
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	66,087	59,562	70,097	60,631	72,134
Operating Profit	16,497	19,178	15,062	19,359	16,687
Net Income Before Taxes	16,497	19,178	15,062	19,359	16,687
Provision for Income Taxes
Net Income After Taxes	14,414	17,801	13,326	16,370	14,066
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	14,714	20,878	35,153	17,941	14,066
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	14,714	20,878	35,153	17,941	14,066
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	6.99	7.14	8.33	7.29	8.33
Dividends per Share